anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Cerebrospinal fluid (CSF) leakage is a common complication of intradural surgery or incidental durotomy in neurosurgery. Dural suturing is a common method for durotomy repair, but this technique requires a long operation time and includes the risk of CSF leakage by incomplete sealing. Glue-type sealants are effective for watertight dural closure. However, unresolved shortcomings include insufficient sealing performance, poor biocompatibility, and excessive swelling. Here, a dural sealant using light-activated hyaluronic acid (HA) with multi-networks (HA photosealant) that provides fast sealing performance and high biocompatibility is reported. The HA photosealants form a watertight hydrogel barrier with multilength networks under low-energy visible light exposure (405 nm, <1 J cm-2) for 5 s and allow firm tissue adhesion on the wet dural surface. In a rabbit model of craniectomy and durotomy, HA photosealants exhibit the faster sealing performance of dural tears and enhance dural repair with accelerated bone formation compared to commercial surgical glues, with no degenerative changes, such as inflammation or necrosis, in histopathological evaluation. This biocompatible HA photosealant can be applied in a variety of clinical settings that require fast wound closure as a promising potential.
FIELD: medicine. SUBSTANCE: invention relates to method of preparing perfluorocarbon emulsions able to transfer oxygen and other gases. Invention describes preparing submicron perfluorocarbon particles of emulsions by homogenization of perfluorocarbons and their mixtures under high pressure from 50 to 1100 atm. The application of sterilization filtration system for prepared perfluorocarbon emulsions allows to obtain the sterilized, more monodispersed, areactogenic (safety), submicron particles of emulsion for medicinal aims. Their maximal diameter does not exceed 0.2 mcm that ensures to enhance safety of clinical application of perfluorocarbon blood substitutes and other media. Invention provides preparing sterile, monodispersed, submicron, areactogenic perfluorocarbon emulsions. Emulsions are designated for artificial perfluorocarbon media and solutions and can be used in medicine as artificial blood, X-ray contrast agents, media for organ preserving and media for development of ointments, gels and cosmetic agents. EFFECT: improved method of preparing, valuable medicinal properties of emulsions. 2 cl, 2 tbl, 1 dwg, 16 ex
A thickened nail polish remover includes a solvent/water blend containing a major amount of organic solvent and a minor amount of water. The nail polish remover also includes a water-wetted thickener that, when dry, is readily dispersible in water but not readily dispersible in the solvent/water blend. The nail polish remover further includes a long chain amine neutralizing agent. The thickened nail polish remover has a viscosity of from 3,000 centipoise to 90,000 centipoise at 21 DEG  C. In one embodiment, the thickened nail polish remover is formulated to be easily rinsable from the nails with water, by selecting a long chain amine neutralizing agent so that the neutralized thickener is compatible both with the solvent/water blend and with the water used to rinse the nails. In the method of preparing the thickened nail polish remover, the thickener is prewetted with the water of the solvent/water blend to form a dispersion of the thickener in the water. The prewetted thickener and water are then mixed with the solvent of the solvent/water blend, and with a long chain amine neutralizing agent, to produce the thickened nail polish remover.
Neonatal pulmonary hemorrhage is a late manifestation of various diseases. Premature delivery and low body weight are frequently observed as high-risk factors, characterized by acute onset, rapid progression, and high mortality rates. Pulmonary hemorrhage caused by cytomegalovirus infection in newborns with normal immune function is a rare occurrence. This case report focuses on a term neonate with normal birth weight who presented solely with nasal obstruction shortly after birth. However, 4 days after birth, the newborn experienced a sudden onset of blood gushing from both the mouth and nasal cavity. The patient was diagnosed with gastrointestinal bleeding, neonatal pneumonia and neonatal lung consolidation. And he was discharged after ten days of symptomatic treatment. However, upon returning home, the patient experienced a sudden onset of bleeding from the mouth and nose, leading to his untimely demise. Subsequent autopsy revealed the presence of pulmonary hemorrhage in newborn, which presented as interstitial pneumonia. The cause of pulmonary hemorrhage is cytomegalovirus infection. This case emphasizes the importance of pediatricians enhancing their skills in differentiating pulmonary hemorrhage, especially from cytomegalovirus pneumonia.
Infectious aortitis is a rare disease process which can be of fungal, viral or bacterial aetiology. This disease process is often incidentally found during concomitant infectious processes, likely due to haematogenous spread. Common sources are from cardiac, genitourinary and gastroenterologic sources. CT imaging of the aorta is essential in identifying physiological changes-wall thickness changes, ectasia and stenosis. We present a case of a female in her early 60s with a medical history of cardiomyopathy with heart failure and reduced ejection fraction, who was initially admitted for acute cholecystitis complicated by the development of gallstone pancreatitis. Imaging evaluation incidentally noted findings consistent with aortitis with a penetrating ulcer, and blood cultures were positive for Staphylococcus aureus bacteraemia, confirming her diagnosis of infectious aortitis. She was started on intravenous antibiotics, required preoperative nutritional optimisation, and subsequently underwent an open aortic resection and aortoiliac reconstruction with rifampin-soaked Dacron graft.
Sleep problems are common for adolescents with psychiatric disorders, and sleep treatment may aid mental health recovery. Inpatient admissions are likely a particularly challenging time for sleep. Despite this little is known about the nature of sleep problems, and how sleep treatments could be optimised for this setting. This mixed-methods study set out to better understand sleep disturbances in adolescent inpatients. Study 1 examined the prevalence of Sleep Condition Indicator-assessed insomnia at admission and associations with psychiatric symptoms and admission length in 100 inpatients (aged 11-17 years) on one unit in Oxford. Data were gathered from admission routine measures and medical records. Associations were analysed using linear regressions. Half of the inpatients (n = 50) screened positive for insomnia at admission. Moderate-large significant associations were observed between more severe insomnia and more severe depression (β = -0.56), anxiety (β = -0.51), self-harm (β = -0.49), psychotic experiences (β = -0.32), and conduct problems (β = -0.30), but not admission length. Study 2 gained 12 clinicians' perspectives on sleep problems on the unit via a focus group and semi-structured interviews, analysed using thematic analysis. Ward staff observed insomnia and excessive daytime sleepiness in adolescent inpatients and a reciprocal relationship with mental health symptoms. Ward processes were barriers (e.g., night-time observations) and facilitators (e.g., regular routines) of sleep. Cognitive behavioural therapy for insomnia was not routinely offered but viewed as potentially helpful. Insomnia may be a common problem for adolescent inpatients, associated with greater psychopathology, but not admission length. The possible benefits of psychological sleep interventions for adolescents admitted to psychiatric units now require testing.
PROBLEM TO BE SOLVED: To provide the method, system and recording medium of a medical chart electronization processing capable of surely securing truthfulness and also securing legibility. SOLUTION: On a pen tablet 8 provided with a display part 81 and a tablet part 82, a chart form as an input picture and the JPEG image of the electronic chart of a previous time as a reference picture are displayed. To the chart form, handwritten characters and sketch images by a stylus pen and text characters/numerical values by a keyboard or the like are written and displayed as medical treatment information. The chart form and the medical treatment information are recorded and preserved in a server 1 or the like by the two kinds of an image file 191 by JPEG and a tagged text file 192. To the two kinds of the files, the same file names for which only expanders are different are imparted.  As a file name, the combined one of the identification information of a doctor or a patient and time information for indicating at least to the unit of second as the medical treatment time is automatically constructed.
Recent advances in laboratory technology have enabled the identification of changes in the genetic makeup of tumors that might be responsible for their malignant behavior such as uncontrolled growth and spread. Some of these changes can be 'druggable', i.e. there may be cancer medicines that can specifically act on the tumour's genetic abnormality. Several cancer centers and programs have initiated this type of molecular profiling across Canada, with the goal to identify 'druggable' changes in tumors to find matching therapy for patients. These include initiatives in British Columbia, Ontario and Quebec. The CAnadian Profiling and Targeted agent Utilization tRial (CAPTUR) will test the activity of a list of commercially available targeted agents in patients who have undergone tumor profiling and have 'druggable' changes identified in their cancers.
All the participants of control (Group II) will receive conventional oral hygiene instructions in presence of their parents. These instructions will be given on model, showing each surface to be cleaned properly. Tooth brushing with the Horizontal Scrub Technique will be promoted and performance of brushing twice daily for 2 minutes. Moreover, avoidance of sugary diet will also be given. However, PECS tool is not used as an intervention in this group. The same instructions will be provided again, one week apart for development of skills.
Chloroquine is rapidly and almost completely absorbed from the gastrointestinal tract, and only a small proportion of the administered dose is found in the stools. Approximately 55% of the drug in the plasma is bound to nondiffusible plasma constituents. Excretion of chloroquine is quite slow but is increased by acidification of the urine. Chloroquine is deposited in the tissues in considerable amounts. In animals, from 200 to 700 times the plasma concentration may be found in the liver, spleen, kidney, and lung; leukocytes also concentrate the drug. The brain and spinal cord, in contrast, contain only 10 to 30 times the amount present in plasma.

Chloroquine undergoes appreciable degradation in the body. The main metabolite is desethylchloroquine, which accounts for one fourth of the total material appearing in the urine; bisdesethylchloroquine, a carboxylic acid derivative, and other metabolic products as yet uncharacterized are found in small amounts. Slightly more than half of the urinary drug products can be accounted for as unchanged chloroquine.
283,265. Kawai, K. Oct. 5, 1926. Medicines for internal use. - A concentrate of cod-liver oil rich in vitamin A is prepared by saponifying 50-75 per cent of the saponifiable portion of ordinary cod-liver oil and then separating the unsaponified oil, containing vitamin A and other effective ingredients, from the saponified matter. The oil may be saponified by adding caustic soda and stirring for about 2 hours at a temperature below 60‹ C. Separation of the saponified and unsaponified matters may be effected by allowing the mass to stand, when the saponified matter sinks to the bottom; the oil at the top is removed, saponified matter remaining therein is extracted bv washing &c., and the oil is then further refined in a centrifugal separating apparatus. Or milk of lime may be added and the mass heated slightly, steam being introduced to prevent oxidation, and, after cooling, the calcium soap is separated from the mass by a filter press or a centrifugal apparatus and then by allowing the mass to stand etc.; or milk of lime and alcohol may be added to the cod-liver oil to effect the saponification.
A remote care device is provided. The remote care device includes a data processing module and a service management module. The data processing module generates a user's service requirement based on a number of health status data for the user of a user account. The service requirement includes the information of user's location, the information of user's demand for service time, and the information of user's demand for service skill. The service management module selects an appropriate service worker option that meets the service requirement from several candidate service worker options. Each of the candidate service worker options includes corresponding service worker positioning information, service worker idle information, and service worker skill information. The service requirement is transmitted to the service worker terminal corresponding to the appropriate service worker option through the communication network.
BACKGROUND: Reproductive toxicity is one of the most important side effects of cisplatin (CIS) and leading to discontinuation of treatment. Syringic acid (SA) is a phenolic acid whose industrial use has increased in recent years due to its antioxidant properties. Recent reports highlight the importance of the supressed Nrf2 pathway in the molecular pathogenesis of CIS toxicity. Therefore, this study aimed to evaluate the therapeutic effect of SA on CIS-induced ovotoxicity through the Nrf2 pathway for the first time.
MATERIAL AND METHODS: Thirty female rats were divided into 5 groups: control, CIS, CIS+SA (5 and 10 mg/kg) and only SA (per se, 10 mg/kg). CIS was administered intraperitoneally at a dose of 5 mg/kg on the 1st day, injections of SA followed by three consecutive days in the rats. Serum anti-mullerian hormone (AMH) levels and ovarian oxidative stress (OS), inflammation, endoplasmic reticulum stress (ERS), apoptosis and Nrf2 pathway markers were determined colorimetrically. Histopathological examinations of the ovaries with hematoxylin and eosin staining were also used to evaluate CIS-induced ovotoxicity.
RESULTS: The CIS treatment depleted serum AMH levels, caused histopathological findings and increased OS, inflammation, ERS and apoptosis levels in ovarian tissue. However, treatments with SA significantly ameliorated CIS-induced biochemical and histopathological changes by activating Nrf2 pathway.
CONCLUSION: The promising adjuvant potential of SA to alleviate CIS-related ovarian damage should be supported by more comprehensive studies.
PURPOSE:To obtain anti-human CEA serum performing the absorptive removal of the anti-NCA antibody in anti-human carcinoembryonic antigen (CEA) serum using a non-specific cross reacting antigen (NCA) of organs of an animal other than human being or an NCA-cotaining substance. CONSTITUTION:For example, a physiological saline solution is added to organs in quantity of 1-2 times and the resulting mixture is homogenized (2,000-5,000rpm) for 5-10min using a blender. An equal quantity of 1.2mol perchloric acid is added to the homogenized mixture obtained under ice cooling and stirring (100-200rpm) is performed for 30-40min to extract NCA. Next, the extract is centrifugally separated at 6,000-8,000rpm for 20-30min and the supernatant liquid obtained is dialyzed in the order of distilled water, sodium hydrogen carbonate and distilled water. Subsequently, the dialysate is centrifugally separated at 8,000-10,000rpm for 20-30min and the supernatant liquid obtained is feeze-dried to obtain an NCA-containing substance. Thereafter, the freeze-dried substance is dissolved in a phosphate buffered saline solution to be mixed with anti-human serum at 4 deg.C and the resulting mixture is allowed to stand for 16hr and subsequently centrifugally separated at 8,000-10,000rpm for 8-10min to obtain a supernatant liquid as purified anti-human CEA serum from which NCA is removed.
BACKGROUND: High-quality patient-reported outcome (PRO) measures for dialysis patients with chronic pruritus are urgently needed. However, no known, well-validated multidimensional tools have been investigated to measure pruritus symptoms in dialysis patients.
OBJECTIVES: To examine the psychometric properties of a multidimensional tool of chronic pruritus, the Uraemic Pruritus in Dialysis patients (UP-Dial) 14-item scale, by comparing haemodialysis and peritoneal dialysis modality.
METHODS: This validation study used data from the Thai Renal Outcomes Research-Uraemic Pruritus, a prospective, multicentre, longitudinal study. Data for this study were collected from 1 February 2019 to 31 May 2022. The adult sample of 226 haemodialysis and 327 peritoneal dialysis patients fulfilled the criteria of chronic pruritus based on the International Forum for the Study of Itch. Psychometric properties of the UP-Dial included validity and reliability, as measured across haemodialysis and peritoneal dialysis patients. Patients completed a set of anchor-based measurement tools, including global itching, Dermatology Life Quality Index (DLQI), EuroQoL-5 dimension-5 level (EQ-5D-5L), Kidney Disease Quality of Life-36 (KDQOL-36), Pittsburgh Sleep Quality Index (PSQI), global fatigue, Somatic Symptom Scale-8 (SSS-8) and Patient Health Questionnaire-9 (PHQ-9).
RESULTS: From the patient's perspective, face validity was satisfactory for both dialysis samples. Psychometric analyses of the UP-Dial for each dialysis sample had good convergent validity. Spearman rho correlations indicate a positively strong correlation (0.73-0.74) with global itching, a positively moderate correlation (0.33-0.58) with DLQI, PSQI, global fatigue, SSS-8 and PHQ-9, and a negatively moderate correlation (-0.39 to -0.58) with EQ-5D-5L and KDQOL-36. The discriminant validity was satisfactory with a group of moderate and severe burden of pruritus for both dialysis samples. For scale reliability, the UP-Dial revealed excellent internal consistency (Cronbach's α = 0.89 and McDonald's ω = 0.90) and reproducibility (intraclass correlation 0.84-0.85) for both dialysis samples. Regarding psychometric properties, no statistically significant differences between dialysis samples were observed (all P > 0.05).
CONCLUSIONS: The findings reaffirm good measurement properties of the UP-Dial 14-item scale in haemodialysis and peritoneal dialysis patients with chronic pruritus. These suggest a transferability of the UP-Dial as a PRO measure in clinical trial and practice settings.
The invention, belonging to the technical field of medicine, relates to a bi-functional anti-platelet aggregation medicine and an application of the medicine in preventing and treating arterial tlirombotic diseases. The medicine of the invention has both a P2Y12 receptor antagonist property and a phosphodiesterase inhibitory activity. The results of in vivo and in vitro anti-platelet aggregation activity experiments of the medicine provide the anti-platelet mechanism of the medicine, the structural formula and anti-platelet mechanism of the medicine are different from those of known anti-platelet medicines, aspirin, Clopidogrel, Prasugrel, Cilostazol, and platelet and fibrinogen receptor antagonist. The medicine of the invention has good inhibition effect to various platelet aggregation induced by agonists. The results of mice in vivo experiment models of arterial thrombosis show that the medicine of the invention has significantly similar antithrombotic activity with Clopidogrel and non-obvious side effect of hemorrhage. The medicine of the invention can be used as antithrombotic medications for treating coronary heart disease, apoplexy and other arterial tlirombotic diseases.
The lumbar facet joints have been implicated as a causal factor in 15 to 40% of patients suffering from chronic low back pain. Because physical examination and medical imaging have limited value in determining the source of pain, diagnostic blocks play an important role in the management of this common condition. Blocks of the L5 dorsal ramus (DR) are used to diagnosed pain originating from the L5-S1 facet joint, which is one of the most commonly implicated levels in patients with low back pain. Fluoroscopic guidance, which uses x-rays, is currently the standard imaging modality used to perform this block. Recently, ultrasound guidance has seen increasing use because of its greater accessibility and lack of ionizing radiation. Although USG has been shown to provide a high level of accuracy at other levels, the greater anatomical complexity found at the L5-S1 has hindered the development of a satisfactory L5 DR block technique. In this study the investigators will use fluoroscopic control to examine the accuracy of a novel ultrasound-guided approach to this block.
After randomization, subjects will take alisartan 120 mg (Salubris, Shenzhen, China) once daily at 6:00-10:00. After 8 weeks of treatment, if the 24-hour ambulatory systolic BP remained ≥ 130 mmHg, alisartan will be doubled to 240mg. After 16 weeks of treatment, if the 24-hour ambulatory systolic BP remained ≥ 130 mmHg, amlodipine besylate 2.5 mg (Dawnrays, Suzhou, China) once daily will be added. The whole treatment duration will last for 24 weeks.
Aranesp is contraindicated in patients with uncontrolled hypertension. In Aranesp clinical studies, approximately 40% of patients with CKD required initiation or intensification of antihypertensive therapy during the early phase of treatment. Hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Aranesp.

Appropriately control hypertension prior to initiation of and during treatment with Aranesp. Reduce or withhold Aranesp if blood pressure becomes difficult to control. Advise patients of the importance of compliance with antihypertensive therapy and dietary restrictions [see Patient Counseling Information (17)].
Each 15 mg tablet for oral administration contains 15 mg of Codeine Sulfate, USP. It is a white, round, uncoated tablet, scored on one side, debossed “15” on the scored side and “LCI” on the other side.

Each 30 mg tablet for oral administration contains 30 mg of Codeine Sulfate, USP. It is a white, round, uncoated tablet, scored on one side, debossed “30” on the scored side and “LCI” on the other side.

Each 60 mg tablet for oral administration contains 60 mg of Codeine Sulfate, USP. It is a white, round, uncoated tablet, scored on one side, debossed “1699” on the scored side and “LCI” on the other side.